Literature DB >> 20004045

Curcuminoid analogs with potent activity against Trypanosoma and Leishmania species.

Chatchawan Changtam1, Harry P de Koning, Hasan Ibrahim, M Sohail Sajid, Matthew K Gould, Apichart Suksamrarn.   

Abstract

The natural curcuminoids curcumin (1), demethoxycurcumin (2) and bisdemethoxycurcumin (3) have been chemically modified to give 46 analogs and 8 pairs of 1:1 mixture of curcuminoid analogs and these parent curcuminoids and their analogs were assessed against protozoa of the Trypanosoma and Leishmania species. The parent curcuminoids exhibited low antitrypanosomal activity (EC(50) for our drug-sensitive Trypanosoma brucei brucei line (WT) of compounds 1, 2 and 3 are 2.5, 4.6 and 7.7 microM, respectively). Among 43 curcuminoid analogs and 8 pairs of 1:1 mixture of curcuminoid analogs tested, 8 pure analogs and 5 isomeric mixtures of analogs exhibited high antitrypanosomal activity in submicromolar order of magnitude. Among these highly active analogs, 1,7-bis(4-hydroxy-3-methoxyphenyl)hept-4-en-3-one (40) was the most active compound, with an EC(50) value of 0.053+/-0.007 microM; it was about 2-fold more active than the standard veterinary drug diminazene aceturate (EC(50) 0.12+/-0.01 microM). Using a previously characterized diminazene-resistant T. b. brucei (TbAT1-KO) and a derived multi-drug resistant line (B48), no cross-resistance of curcuminoids was observed to the diamidine and melaminophenyl arsenical drugs that are the current treatments. Indeed, curcuminoids carrying a conjugated keto (enone) motif, including 40, were significantly more active against T. b. brucei B48. This enone motif was found to contribute to particularly high trypanocidal activity against all Trypanosoma species and strains tested. The parent curcuminoids showed low antileishmanial activity (EC(50) values of compounds 1 and 2 for Leishmania mexicana amastigotes are 16+/-3 and 37+/-6 microM, respectively) while the control drug, pentamidine, displayed an EC(50) of 16+/-2 microM. Among the active curcuminoid analogs, four compounds exhibited EC(50) values of less than 5 microM against Leishmania major promastigotes and four against L. mexicana amastigotes. No significant difference in sensitivity to curcuminoids between L. major promastigotes and L. mexicana amastigotes was observed. The parent curcuminoids and most of their analogs were also tested for their toxicity against human embryonic kidney (HEK) cells. All the curcuminoids exhibited lower toxicity to HEK cells than to T. b. brucei bloodstream forms and only one of the tested compounds showed significantly higher activity against HEK cells than curcumin (1). The selectivity index for T. b. brucei ranged from 3-fold to 1500-fold. The selectivity index for the most active analog, the enone 40, was 453-fold. Copyright (c) 2009 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 20004045     DOI: 10.1016/j.ejmech.2009.11.035

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   6.514


  31 in total

1.  Association of Neuroprotective Effect of Di-O-Demethylcurcumin on Aβ25-35-Induced Neurotoxicity with Suppression of NF-κB and Activation of Nrf2.

Authors:  Decha Pinkaew; Chatchawan Changtam; Chainarong Tocharus; Piyarat Govitrapong; Pichaya Jumnongprakhon; Apichart Suksamrarn; Jiraporn Tocharus
Journal:  Neurotox Res       Date:  2015-09-10       Impact factor: 3.911

2.  Curcumin and its derivatives: their application in neuropharmacology and neuroscience in the 21st century.

Authors:  Wing-Hin Lee; Ching-Yee Loo; Mary Bebawy; Frederick Luk; Rebecca S Mason; Ramin Rohanizadeh
Journal:  Curr Neuropharmacol       Date:  2013-07       Impact factor: 7.363

Review 3.  Recent developments in drug discovery for leishmaniasis and human African trypanosomiasis.

Authors:  Advait S Nagle; Shilpi Khare; Arun Babu Kumar; Frantisek Supek; Andriy Buchynskyy; Casey J N Mathison; Naveen Kumar Chennamaneni; Nagendar Pendem; Frederick S Buckner; Michael H Gelb; Valentina Molteni
Journal:  Chem Rev       Date:  2014-11-03       Impact factor: 60.622

4.  In vitro efficacy of curcumin on Trichomonas vaginalis.

Authors:  Benjamin Wachter; Michael Syrowatka; Andreas Obwaller; Julia Walochnik
Journal:  Wien Klin Wochenschr       Date:  2014-03-12       Impact factor: 1.704

5.  SAR Studies of Diphenyl Cationic Trypanocides: Superior Activity of Phosphonium over Ammonium Salts.

Authors:  Christophe Dardonville; Abdulsalam A M Alkhaldi; Harry P De Koning
Journal:  ACS Med Chem Lett       Date:  2014-12-10       Impact factor: 4.345

Review 6.  Biological activities of curcuminoids, other biomolecules from turmeric and their derivatives - A review.

Authors:  Augustine Amalraj; Anitha Pius; Sreerag Gopi; Sreeraj Gopi
Journal:  J Tradit Complement Med       Date:  2016-06-15

7.  Hexahydrocurcumin enhances inhibitory effect of 5-fluorouracil on HT-29 human colon cancer cells.

Authors:  Khanitta Srimuangwong; Chainarong Tocharus; Pornphrom Yoysungnoen Chintana; Apichart Suksamrarn; Jiraporn Tocharus
Journal:  World J Gastroenterol       Date:  2012-05-21       Impact factor: 5.742

8.  Effects of hexahydrocurcumin in combination with 5-fluorouracil on dimethylhydrazine-induced colon cancer in rats.

Authors:  Khanitta Srimuangwong; Chainarong Tocharus; Jiraporn Tocharus; Apichart Suksamrarn; Pornphorm Yoysungnoen Chintana
Journal:  World J Gastroenterol       Date:  2012-12-21       Impact factor: 5.742

9.  Development of Gelucire® 48/16 and TPGS Mixed Micelles and Its Pellet Formulation by Extrusion Spheronization Technique for Dissolution Rate Enhancement of Curcumin.

Authors:  Umesh K Shinde; Dilipkumar G Suryawanshi; Purnima D Amin
Journal:  AAPS PharmSciTech       Date:  2021-06-15       Impact factor: 3.246

10.  Inhibitory Effect of Hexahydrocurcumin on Memory Impairment and Amyloidogenesis in Dexamethasone-Treated Mice.

Authors:  Pranglada Jearjaroen; Kanet Pakdeepak; Chainarong Tocharus; Waraluck Chaichompoo; Apichart Suksamrarn; Jiraporn Tocharus
Journal:  Neurotox Res       Date:  2020-08-27       Impact factor: 3.911

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.